Carpenter Technology Corporation heads into its Q3 2026 results — due after the close today — with the most intriguing tension being the dramatic unwinding of short positions against a stock that has already rallied 36% year-to-date.
Short interest has been cut almost in half since late March, and that compression tells the clearest story of the week. At the peak in mid-March, shorts held roughly 3.1 million shares. By April 28, that had collapsed to just over 2.0 million — 4.0% of free float. The drop is concentrated in the six weeks ahead of today's print, with the 30-day change running at -35%. Borrow conditions confirm there is no stress in the lending market: the cost to borrow sits at 0.41%, essentially unchanged over the month, and availability is extremely loose at over 1,140% of short interest. That means for every share currently borrowed short, eleven more are sitting available in the lending pool. Shorts have been heading for the exits voluntarily, not squeezed out.
Options positioning is broadly neutral, which reinforces the picture of a market that has already made up its mind on CRS. The put/call ratio came in at 0.75 on Tuesday — just a quarter of a standard deviation above its 20-day mean of 0.72. That is well within the normal range, and far below the 52-week high of 1.12 seen when the market was genuinely defensive on this name. The short score has nudged up to 38.1 from a recent low of 34.8 midweek — a very modest pickup, not a directional alarm. Overall, positioning looks constructive rather than cautious.
The Street has been busy lifting targets ahead of today's report. JP Morgan's Bennett Moore — the most active follower here — raised his target to $465 from $394 on April 20, maintaining Overweight. Keybanc moved similarly, lifting to $453. Wells Fargo initiated at Equal-Weight with a $400 target on April 1, and Susquehanna started coverage at Positive in March with a $470 target. The mean target of $439 sits just 2.5% above the current price of $428, which is a narrow gap given the calibre of the bull case — it implies the Street views the stock as broadly fairly valued at current levels rather than deeply undervalued. The PE has expanded roughly 4.5 turns over the past month to 39x, and the price-to-book has climbed more than 1.2 turns in the same period. Bulls point to aerospace and defence bookings up 23% quarter-over-quarter and expanding margins in Specialty Alloys. Bears flag the sequential decline in price and EBITDA per pound — the first since early fiscal 2023 — and a 20% drop in medical sales due to distributor destocking.
One notable institutional development: FMR (Fidelity) added 527,000 shares in the quarter to March 31, lifting their stake to 7.4% of shares. Lone Pine initiated a brand-new position of 1.3 million shares — nearly 2.6% of the company — also in Q4 2025. Those are meaningful new commitments from active managers, and they sit in contrast to the insider picture, where General Counsel James Dee sold roughly $6.2 million of stock in late February and an independent director sold a further $2.5 million. Insider selling at these price levels is worth noting, though the trades were executed near $390-393 — well below today's close — so the sellers left money on the table.
One prior earnings reaction in the data: the January 29 print saw the stock fall 4.2% on the day, then recover to gain 5.1% over the following five days. The previous quarter's report therefore fits a pattern of initial disappointment followed by a quick reversal — a setup that tends to favour patience over immediate reaction.
The focal point for the rest of today is simple: whether the sequential pressure on Specialty Alloys margins is stabilising or deepening, and whether the aerospace bookings strength continues to offset the medical softness.
See the live data behind this article on ORTEX.
Open CRS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
